岭南现代临床外科 ›› 2023, Vol. 23 ›› Issue (03): 283-288.DOI: 10.3969/j.issn.1009-976X.2023.03.013
• 综述 • 上一篇
王玉波, 罗斌, 马琳, 任贺成, 尹龙, 黄楹*
通讯作者:
*黄楹,Email:Yinghuang00@aliyun.com
WANG Yu-bo, MA Lin, REN He-cheng, LUO Bin, HUANG Ying
Received:
2022-11-14
Published:
2023-08-04
Contact:
HUANG Ying, yinghuang00@aliyun.com
摘要: 烟雾病又称自发性基底动脉环闭塞症,是一种以颈内动脉末端及大脑前、大脑中动脉起始部动脉内膜缓慢增厚,动脉管腔逐渐狭窄以至闭塞,脑底穿通动脉代偿性扩张为特征的疾病。本篇文章将对近年来烟雾病的东亚流行病学特征及其临床特点作一综述。
中图分类号:
王玉波, 罗斌, 马琳, 任贺成, 尹龙, 黄楹. 烟雾病的研究进展[J]. 岭南现代临床外科, 2023, 23(03): 283-288.
WANG Yu-bo, MA Lin, REN He-cheng, LUO Bin, HUANG Ying. Research progress on moyamoya disease[J]. Lingnan Modern Clinics In Surgery, 2023, 23(03): 283-288.
[1] Hishikawa T, Sugiu K, Date I.Moyamoya Disease: A Review of Clinical Research[J]. Acta Med Okayama, 2016, 70(4): 229-236. [2] Hu J, J Luo, Q Chen. The Susceptibility Pathogenesis of Moyamoya Disease[J]. World Neurosurg, 2017, 101: 731-741. [3] Jang MA, Chung JW, Yeon JY, et al.Frequency and significance of rare RNF213 variants in patients with adult moyamoya disease[J]. PLoS One, 2017, 12(6): e0179689. [4] Wang Y, Mambiya M, Li Q, et al.RNF213 p.R4810K Polymorphism and the Risk of Moyamoya Disease, Intracranial Major Artery Stenosis/Occlusion, and Quasi-Moyamoya Disease: A Meta-Analysis[J]. J Stroke Cerebrovasc Dis, 2018, 27(8): 2259-2270. [5] Nomura S, Yamaguchi K, Akagawa H, et al.Genotype-Phenotype Correlation in Long-Term Cohort of Japanese Patients withMoyamoya Disease[J]. Cerebrovasc Dis, 2019, 47(3-4): 105-111. [6] Ahn IM, Park DH, Hann HJ, et al.Incidence, prevalence, and survival of moyamoya disease in Korea: a nationwide,population-based study[J]. Stroke, 2014, 45(4): 1090-1095. [7] Chen PC, Yang SH, Chien KL, et al.Epidemiology of moyamoya disease in Taiwan: a nationwide population-based study[J]. Stroke, 2014, 45(5): 1258-1263. [8] Miao W, Zhao PL, Zhang YS, et al.Epidemiological and clinical features of Moyamoya disease in Nanjing, China[J]. Clin Neurol Neurosurg, 2010, 112(3): 199-203. [9] Duan L, Bao XY, Yang WZ, et al.Moyamoya disease in China: its clinical features and outcomes[J]. Stroke, 2012, 43(1): 56-60. [10] Miyakoshi A, Funaki T, Fushimi Y, et al.Cortical Distribution of Fragile Periventricular Anastomotic Collateral Vessels in Moyamoya Disease: An Exploratory Cross-Sectional Study of Japanese Patients with Moyamoya Disease[J]. AJNR Am J Neuroradiol, 2020, 41(12): 2243-2249. [11] Ge P, Ye X, Zhang Q, et al.Clinical features, surgical treatment, and outcome of intracranial aneurysms associated with moyamoya disease[J]. J Clin Neurosci, 2020, 80: 274-279. [12] Kwon HS, Kim YS, Lee JM,et al.Causes, Risk Factors, and Clinical Outcomes of Stroke in Korean Young Adults: Systemic Lupus Erythematosus is Associated with Unfavorable Outcomes[J]. J Clin Neurol, 2020, 16(4): 605-611. [13] Shang S, Zhou D, Ya J, et al.Progress in moyamoya disease[J]. Neurosurg Rev, 2020, 43(2): 371-382. [14] Wakai K, Tamakoshi A, Ikezaki K, et al.Epidemiological features of moyamoya disease in Japan: findings from a nationwide survey[J]. Clin Neurol Neurosurg, 1997, 99(Suppl 2): S1-5. [15] Baba T, Houkin K, Kuroda S.Novel epidemiological features of moyamoya disease[J]. J Neurol Neurosurg Psychiatry, 2008, 79(8): 900-904. [16] Kim JS.Moyamoya Disease: Epidemiology, Clinical Features, and Diagnosis[J]. J Stroke, 2016, 18(1): 2-11. [17] Kuriyama S, Kusaka Y, Fujimura M,et al.Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey[J]. Stroke, 2008, 39(1): 42-47. [18] Im SH, Cho CB, Joo WI,et al, Prevalence and epidemiological features of moyamoya disease in Korea[J]. J Cerebrovasc Endovasc Neurosurg, 2012, 14(2): 75-78. [19] Huang S, Guo ZN, Shi M et al. Etiology and pathogenesis of Moyamoya Disease: An update on disease prevalence[J]. Int J Stroke, 2017, 12(3): 246-253. [20] 付雄洁,曾翰海,芦晓阳, 等. 烟雾病和烟雾综合征[J]. 浙江医学, 2017, 39(23): 2175-2178. [21] 王孟杰, 崔昌萌,马文渊, 等. 烟雾病发病机制的研究进展[J]. 中国临床实用医学, 2021, 12(2): 78-80. [22] Ikezaki K, Han DH, Kawano T, et al.A clinical comparison of definite moyamoya disease between South Korea and Japan[J]. Stroke, 1997 28(12): 2513-2517. [23] Gaillard J, Klein J, Duran D, et al.Incidence, clinical features, and treatment of familial moyamoya in pediatric patients: a single-institution series[J]. J Neurosurg Pediatr, 2017, 19(5): 553-559. [24] Gupta A, Tyagi A, Romo M, et al.Moyamoya Disease: A Review of Current Literature[J]. Cureus, 2020, 12(8): e10141. [25] Acker G, Goerdes S, Schneider UC, et al.Distinct clinical and radiographic characteristics of moyamoya disease amongst European Caucasians[J]. Eur J Neurol, 2015, 22(6): 1012-1017. [26] Research Committee on the Pathology and Treatment of Spontaneous Occlusion of the Circle of Willis, Health Labour Sciences Research Grant for Research on Measures for Infractable Diseases. Guidelines for Diagnosis and Treatment of Moyamoya Disease (Spontaneous Occlusion of the Circle of Willis)[J]. Neurologia medico-chirurgica, 2012, 52(5): 245-266. [27] Horn P, Bueltmann E, Buch CV, et al.Arterio-embolic ischemic stroke in children with moyamoya disease[J]. Childs Nerv Syst, 2005, 21(2): 104-107. [28] Liu ZW, Han C, Wang H, et al.Clinical characteristics and leptomeningeal collateral?status in pediatric andadult patients with ischemic moyamoya disease[J]. CNS Neurosci Ther, 2020, 26(1): 14-20. [29] Tashiro R, Fujimura M, Sakata H, et al.Genetic analysis of ring finger protein 213 (RNF213) c.14576G>A polymorphism inpatients with vertebral artery dissection: a comparative study with moyamoyadisease[J]. Neurol Res, 2019, 41(9): 811-816. [30] Cho WS, Kim JE, Kim CH, et al.Long-term outcomes after combined revascularization surgery in adult moyamoya disease[J]. Stroke, 2014, 45(10): 3025-3031. [31] Kim SK, Cho BK, Phi JH, et al.Pediatric moyamoya disease: An analysis of 410 consecutive cases[J]. Ann Neurol, 2010, 68(1): 92-101. [32] Kim JM, Lee SH, Roh JK.Changing ischaemic lesion patterns in adult moyamoya disease[J]. J Neurol Neurosurg Psychiatry, 2009, 80(1): 36-40. [33] Hishikawa T, Tokunaga K, Sugiu K, et al.Assessment of the difference in posterior circulation involvement between pediatric and adult patients with moyamoya disease[J]. J Neurosurg, 2013, 119(4): 961-965. [34] Lee JY, Kim SK, Phi JH, et al, Posterior Cerebral Artery Insufficiency in Pediatric Moyamoya Disease[J]. J Korean Neurosurg Soc, 2015, 57(6): 436-439. [35] Hallemeier CL, Rich KM, Grubb RL Jr, et al.Clinical features and outcome in North American adults with moyamoya phenomenon[J]. Stroke, 2006, 37(6): 1490-1496. [36] Funaki T, Takahashi JC, Houkin K, et al.Effect of choroidal collateral vessels on de novo hemorrhage in moyamoya disease: analysis of nonhemorrhagic hemispheres in the Japan Adult Moyamoya Trial[J]. J Neurosurg, 2019, 132(2): 408-414. [37] Nah HW, Kwon SU, Kang DW, et al.Moyamoya disease-related versus primary intracerebral hemorrhage: [corrected]location and outcomes are different[J]. Stroke, 2012, 43(7): 1947-1950. [38] Sun W, Yuan C, Liu W, et al.Asymptomatic cerebral microbleeds in adult patients with moyamoya disease: a prospective cohort study with 2 years of follow-up[J]. Cerebrovasc Dis, 2013, 35(5): 469-475. [39] Kazumata K, Shinbo D, Ito M, et al.Spatial relationship between cerebral microbleeds, moyamoya vessels, and hematoma in moyamoya disease[J]. J Stroke Cerebrovasc Dis, 2014, 23(6): 1421-1428. [40] Yilmaz EY, Pritz MB, Bruno A, et al.Moyamoya: Indiana University Medical Center experience[J]. Arch Neurol, 2001, 58(8): 1274-1278. [41] Hogan AM, Kirkham FJ, Isaacs EB, et al.Intellectual decline in children with moyamoya and sickle cell anaemia[J]. Dev Med Child Neurol, 2005, 47(12): 824-829. [42] 许佳宁,王华. 影响RNF213基因相关烟雾病预后的研究进展[J]. 中国实用儿科杂志, 2022,37(07): 550-556. [43] Seol HJ, Wang KC, Kim SK,et al.Headache in pediatric moyamoya disease: review of 204 consecutive cases[J]. J Neurosurg, 2005, 103(5 Suppl): 439-442. [44] Park-Matsumoto YC, Tazawa T, Shimizu J.Migraine with aura-like headache associated with moyamoya disease[J]. Acta Neurol Scand, 1999, 100(2): 119-121. [45] Kuroda S, Houkin K.Moyamoya disease: current concepts and future perspectives[J]. Lancet Neurol, 2008, 7(11): 1056-1066. [46] . Wouters A, Smets I, Van den Noortgate W, et al. Cerebrovascular events after surgery versus conservative therapy for moyamoya disease: a meta-analysis[J]. Acta Neurol Belg, 2019, 119(3): 305-313. [47] Miyamoto S, Yoshimoto T, Hashimoto N, et al.Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease: results of the Japan Adult Moyamoya Trial[J]. Stroke, 2014, 45(5): 1415-1421. [48] Wang G, Zhang X, Feng M, et al.Efficacy of Surgical Treatment on the Recurrent Stroke Prevention for Adult Patients With Hemorrhagic Moyamoya Disease[J]. J Craniofac Surg, 2017, 28(8): 2113-2116. [49] Takahashi JC, Funaki T, Houkin K, et al.Significance of the Hemorrhagic Site for Recurrent Bleeding: Prespecified Analysis in the Japan Adult Moyamoya Trial[J]. Stroke, 2016, 47(1): 37-43. [50] 徐斌,顾宇翔. 烟雾病和烟雾综合征诊断与治疗中国专家共识(2017)[J]. 中华神经外科杂志, 2017, 33(6): 541-547. [51] Kawashima A, Kawamata T, Yamaguchi K, et al.Successful superficial temporal artery-anterior cerebral artery direct bypass using a long graft for moyamoya disease: technical note[J]. Neurosurgery, 2010, 67(3 Suppl Operative): 145-149. [52] Hayashi T, Shirane R, Tominaga T. Additional surgery for postoperative ischemic symptoms in patients with moyamoya disease: the effectiveness of occipital artery-posterior cerebral artery bypass with an indirect procedure: technical case report [J]. Neurosurgery, 2009, 64(1): E195-196; discussion E196. [53] Rashad S, Fujimura M, Niizuma K, et al.Long-term follow-up of pediatric moyamoya disease treated by combined direct-indirect revascularization surgery: single institute experience with surgical and perioperative management[J]. Neurosurg Rev, 2016, 39(4): 615-623. [54] Mizoi K, Kayama T, Yoshimoto T,et al. Indirect revascularization for moyamoya disease: is there a beneficial effect for adult patients?[J]. Surg Neurol,1996, 45(6):541-548;discussion 548-549. [55] Ando S,Tsutsui S,Miyoshi K,et al.Cilostazol may improve cognition better than clopidogrel in non-surgical adult patients withischemic moyamoya disease: subanalysis of a prospective cohort[J]. Neurol Res,2019, 41(5): 480-487. [56] Kazumata,K.Which is the Optimal Revascularization SurgeryinMoyamoya Disease?[J]. World Neurosurg,2020, 139: 616-617. [57] Li Q,Gao Y,Xin W,et al.Meta-Analysis of Prognosis of Different Treatments for Symptomatic Moyamoya Disease[J]. WorldNeurosurg, 2019, 127: 354-361. [58] Fung L W,Thompson D,Ganesan V.Thompson and V.Ganesan,Revascularisation surgery for paediatric moyamoya: areview of the literature[J]. Childs NervSyst,2005, 21(5): 358-364. [59] Kazumata K,Ito M,Tokairin K,et al.The frequency of postoperative stroke in moyamoya disease following combined revascularization: a single-university seriesandsy stematic review[J].J Neuro Surg, 2014, 121(2): 432-340. [60] Mugikura S,Higano S,Shirane R,et al.Posterior circulation and high prevalence of ischemic stroke among young pediatric patients with Moyamoya disease: evidence of angiography-based differences by age at diagnosis[J]. AJNR Am J Neuro Radiol,2011, 32(1): 192-198. [61] Funaki T,Takahashi JC,Takagi Y,et al.Impact of posterior cerebral artery involvement on long-term clinical and social outcome of pediatric moyamoya disease[J]. J Neurosurg Pediatr,2013, 12(6): 626-632. [62] Hishikawa T,Tokunaga K,Sugiu K,et al.Long-term outcomes in adult patients with ischemic-type moyamoya disease involving posterior circulation[J]. Acta Neurochir(Wien),2014, 156(9): 1745-1751. [63] Kobayashi E,Saeki N,Oishi H.Long-term natural history of hemorrhagic moyamoya disease in 42 patients[J]. J Neurosurg,2000, 93(6): 976-980. [64] 孙玮良,赵黎明,梁浩,等.烟雾病的临床特征及外科治疗的流行病学分析[J].中国实用神经疾病杂志,2020, 23(6): 485-490. |
[1] | 李海涛, 于洋, 吴静超, 吴璠, 王玥, 梁思泉. 帕金森病患者脑深部电刺激术后综合管理对其平衡障碍的作用研究[J]. 岭南现代临床外科, 2023, 23(01): 42-48. |
[2] | 杨与敏, 韩杨云, 龙晓东, 李爱国, 梁小龙, 叶峰, 邹林波, 刘之彝. 术中ICG荧光血管造影在出血性脑动静脉畸形切除术中的应用体会[J]. 岭南现代临床外科, 2022, 22(06): 570-572. |
[3] | 张博浩, 陈蕾. 脑梗死后致华勒变性1例报告[J]. 岭南现代临床外科, 2020, 20(06): 807-809. |
[4] | 顾威庭, 赵俊文, 赵东明, 成侃, 蔡瑜. 微侵袭血肿清除术对高血压脑出血患者术后神经功能恢复及并发症的影响[J]. 岭南现代临床外科, 2020, 20(04): 463-467. |
[5] | 李万春, 高岩升. 无症状颈动脉粥样硬化斑块内出血与冠状动脉支架植入手术后脑梗塞和死亡的分析[J]. 岭南现代临床外科, 2020, 20(03): 367-370. |
[6] | 程磊, 李旭东, 王世波, 范一木. 动脉粥样硬化相关的前循环大血管闭塞所致急性缺血性卒中的血管内治疗[J]. 岭南现代临床外科, 2020, 20(01): 98-101. |
[7] | 陈晓晨, 任雪娇, 高伟伟, 岳树源. 孕酮调节创伤性脑损伤后炎症反应及预后的实验研究[J]. 岭南现代临床外科, 2020, 20(01): 84-92. |
[8] | 张海红, 陈晓晨, 何山, 施铭岗. 硬脑膜补丁修补法与普通硬脑膜缝合在关于后颅窝手术术后并发症的比较[J]. 岭南现代临床外科, 2019, 19(06): 714-716. |
[9] | 冯家强, 余瑞钿, 罗江兵, 李立峰. 近红外光谱技术在高血压脑出血术中监测运用的探讨[J]. 岭南现代临床外科, 2019, 19(05): 576-579. |
[10] | 卓少伟,师少春,黄柳军,林小义,秦康威,张准仪,蔡树嘉,张曙佳*. 高血压脑出血引流术后再出血和感染的观察分析[J]. 岭南现代临床外科, 2019, 19(05): 608-613. |
[11] | 何竞斯, 梁双弟, 劳惠玲, 谭晓穗*. 神经内镜下行基底节脑出血血肿清除术的临床体会[J]. 岭南现代临床外科, 2019, 19(04): 467-471. |
[12] | 杨与敏,刘之彝,龙晓东,李爱国,李凤,秦兴虎. 终板造瘘对动脉瘤性蛛网膜下腔出血导致慢性脑积水的疗效[J]. 岭南现代临床外科, 2019, 19(03): 321-328. |
[13] | 陆小蒟*, 容永璋, 冯家强, 李晓霞. 脑脊液降钙素原及乳酸测定在早期诊断颅脑术后颅内感染的意义[J]. 岭南现代临床外科, 2019, 19(01): 83-85. |
[14] | 陈钦标1, 郭泳彤2, 胡智2, 赵义营1, 刘正豪1, 周志威1, 黄毓韬1,邓跃飞1, 雷炳喜1*. 颅骨骨膜减张修补硬脑膜在急性小脑幕切迹疝去骨瓣减压手术中的应用[J]. 岭南现代临床外科, 2018, 18(03): 353-356. |
[15] | 刘锦仪 雷伟健 欧阳婵 余炳坚 . 脑电监测α变异百分率与重型急性脑梗死发病 90天预后的相关性研究[J]. 岭南现代临床外科, 2017, 17(06): 658-664. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||